



MBI 2017 Meeting: 30th Nov– 1st Dec Trinity College Dublin

MBI 2017 Meeting

This year's meeting takes place in Trinity College Dublin, the University of Dublin at the Trinity Biosciences Institute. We are looking forward to an excellent program with leading international experts working to share and discuss latest advances in the fields of matrix biology. The scope of the meeting is to promote and consolidate scientific interest and expertise around extracellular matrix research in all its forms within Ireland, and, to link this with the international scientific community on Matrix Biology. The main theme of this year's meeting is 'Learning from Development to Engineering Therapeutics'.

Abstract Submission Deadline: 10th October

Early Bird Registration: 13th October

ABSTRACT SUBMISSION

REGISTRATION

Track Themes

- Immunology and Immunotherapy
- ECM Signaling in Development
- ECM Signalling in Fibrosis
- Matrix Biology and the Tumour Microenvironment
- Bioengineering Approaches using Matrix Proteins
- ECM and its interactions with Immunotherapy
- Advanced Emerging Imaging Technologies of ECM
- Harnessing ECM as a Therapeutic

Confirmed Speakers

[George Bou-Gharios](#)

[John Baugh](#)

[John Robert Couchman](#)

[Adam J. Engler](#)

[Karen English](#)

[Peter Friedl](#)

[Caitriona Lally](#)

[Tanya Levingstone](#)

[Charles D. Little](#)

[Aideen Ryan](#)

[Liliana Schaefer](#)

[Charles Streuli](#)

This year's meeting schedule will provide ample opportunity for informal discussions and networking. Guided poster tours, rapid-fire presentations as well as poster prizes will be dedicated to your scientific contributions. Additionally, a strong focus on emerging and young investigator presentations will be facilitated during the meeting.



Silver Sponsor



Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to develop technologies that improve and enhance life—from biopharmaceutical therapies to treat cancer or multiple sclerosis, systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. The life science business' purpose is to solve the toughest problems in the industry by collaborating with the global scientific community. With a broad portfolio of more than 300,000 products for protein research, cell biology and chemical-based and biopharmaceuticals, the business covers the bioprocessing value chain.

